Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesPhenotype and Genotype-Infectious AgentsCPT cpt-87906-hiv-1-genotype-nucleic-acid-non-rt-protease-regions
    Ask Trek AI about this page

    CPT 87906: HIV‑1 Genotype by Nucleic Acid (non-RT/protease)

    CPT code 87906 reports a laboratory technical procedure for nucleic acid analysis to determine the genotype of an HIV‑1 virus in regions other than the reverse transcriptase and protease genes (for example, integrase or fusion genes); this service is a molecular virology genotyping test performed by a laboratory analyst and is typically provided as a specialized laboratory (molecular pathology/microbiology) service in clinical laboratory or reference laboratory settings.

    For related coverage guidance, see recent payer policy updates: Biomarker Testing for Autoimmune Rheumatic Disease, Immunopharmacologic Monitoring of Therapeutic Serum Antibodies, Immune Cell Function Assay.

    Customize your policy alerts

    Sign up for cpt 87906 policy alerts

    Get alerted when payer policies referencing 87906 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 42-year-old person with known HIV-1 infection presents for evaluation following suboptimal viral suppression on current antiretroviral therapy. The treating infectious disease clinician orders genotypic resistance testing focused on the HIV-1 integrase gene to detect mutations that confer resistance to integrase strand transfer inhibitors. A blood specimen (plasma) is collected in the outpatient infusion clinic or ambulatory lab and sent to a molecular diagnostics laboratory. The laboratory analyst performs nucleic acid extraction, sequencing or targeted genotyping of regions other than reverse transcriptase and protease (for example, the integrase gene), interprets the technical assay results, and reports detected resistance-associated substitutions to the ordering clinician. Typical site of service includes outpatient ambulatory clinics, hospital outpatient departments, and reference molecular laboratories. Typical workflow steps: specimen collection → specimen accessioning and nucleic acid extraction → amplification/sequencing or targeted assay of integrase/fusion regions → bioinformatic analysis and quality control → technical result reporting to the laboratory information system (with or without separate professional interpretation by a clinical molecular pathologist).

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    87491Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, amplified probe technique, qualitativeExample of a nucleic acid amplification detection CPT used for viral identification; represents similar laboratory methodology (amplification platforms) though not specific to HIV genotyping.
    87536Infectious agent detection by nucleic acid (DNA or RNA), direct probe technique; HIV-1 quantificationRepresents viral load testing often performed before or concurrently with genotypic resistance testing to assess viremia level.
    88260Tissue culture for viral isolation, any source; with identification of viral agentRepresents virology methods sometimes used in comprehensive viral testing workflows; less commonly used for modern genotypic assays.
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stainExample laboratory code for ancillary testing workflows that may be bundled with pathology services when tissue-based viral testing is indicated.
    87907Laboratory analysis of genotype of HIV-1 virus by nucleic acid, reverse transcriptase and protease regions; (example companion code)Related genotypic testing of different HIV-1 coding regions (reverse transcriptase and protease) commonly ordered alongside integrase genotyping to provide a full resistance profile.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207K00000X
    363L00000X
    207L00000X
    2084P0800X
    323P00000X
    163WD0400X
    204C00000X
    207XX0004X

    Related Payer Policy Updates

    Specialty: Immunology/Rheumatology1 / 3

    10 rows

    PolicyPayerEffective Date
    Biomarker Testing for Autoimmune Rheumatic DiseaseOscar Health2026-10-01
    Immunopharmacologic Monitoring of Therapeutic Serum AntibodiesOscar Health2026-10-01
    Immune Cell Function AssayOscar Health2026-10-01
    Biomarker Testing for Autoimmune Rheumatic DiseaseBlue Cross Blue Shield - New Mexico2026-09-04
    Inflammatory Conditions - Orencia Intravenous Preferred Specialty Management Policy for Legacy Prescription Drug ListsCigna2026-09-01
    Secukinumab (Cosentyx) — intravenous (Medicare Advantage)blue cross blue shield - louisiana2026-09-01
    Intravenous Immune Globulin (IVIG) — indications and authorization criteriaBlue Cross Blue Shield - Iowa2026-08-28
    Infliximab Intravenous Products Preferred Specialty Management PolicyCigna2026-08-15
    Kineret (anakinra) — Coverage CriteriaBlue Cross Blue Shield - Iowa2026-08-14
    Actimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteriameridian_health_plan_of_michigan2026-08-01

    Related Codes

    CPT-87900-VIRAL-DRUG-SUSCEPTIBILITY-GENOTYPIC-PHENOTYPE-PREDICTION

    CPT 87900: Viral Drug Susceptibility and Phenotype Prediction

    CPT-87901-HIV-1-GENOTYPE-REVERSE-TRANSCRIPTASE-PROTEASE-ANALYSIS

    CPT 87901: HIV‑1 Genotype — Protease and Reverse Transcriptase Sequencing

    CPT-87902-HEPATITIS-C-GENOTYPE-NUCLEIC-ACID-TESTING-TECHNICAL

    CPT 87902: Hepatitis C Virus Genotype by Nucleic Acid Analysis

    CPT-87903-HIV-1-DRUG-RESISTANCE-NUCLEIC-ACID-ANALYSIS

    CPT 87903: HIV-1 Drug Resistance Testing, Culture-Based

    CPT-87904-HIV-1-DRUG-RESISTANCE-ADDITIONAL-DRUG-TESTING

    CPT 87904: HIV‑1 Drug Resistance Test, Additional Drug

    CPT-87905-ENZYMATIC-ACTIVITY-TESTING-INFECTIOUS-AGENT-TECHNICAL

    CPT 87905: Enzymatic Activity Test for Non-Viral Infectious Agents

    CPT-87910-CMV-GENOTYPE-NUCLEIC-ACID-ANALYSIS

    CPT 87910: CMV Genotype Analysis by Nucleic Acid Testing

    CPT-87912-HEPATITIS-B-GENOTYPE-ANALYSIS-NUCLEIC-ACID

    CPT 87912: Hepatitis B Virus Genotype Analysis

    CPT-87913-SARS-COV-2-GENOTYPE-ANALYSIS-NEXT-GENERATION-SEQUENCING

    CPT 87913: SARS–CoV–2 Genotype Analysis by Next‑Generation Sequencing

    CPT-87999-UNLISTED-MICROBIOLOGY-PROCEDURE

    CPT 87999: Unlisted Microbiology Procedure

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.